Specific Anti-HIV Antibodies In HIV-Infected And AIDS Patients Who Received Antiretroviral Therapy For The First Time In Jiangmen Prefecture,Guangdong Province

Background and ObjectiveHIV antibodies,in patients associated with durable virologic suppression,as a useful predictor of monitoring the effect of antiretroviral therapy(ART).But studies investigating in anti-HIV antibody response and significance among patients who initiating therapy during acute or chronic phase have reached inconsistent conclusion.The purpose of the study was to describe the levels and trends of HIV-1-specific antibodies in AIDS patients who received antiretroviral therapy(ART)for the first time compared to chronically HIV-1 infected.On the basis of this data,comparing the rate of decline,the suppression degree and the clearance time in anti-HIV-1 antibody between the two groups.We compared HIV antibody responses to both viral load and CD4+T cell in patients who initiated ART early and later HIV infection.It provides basic data for monitoring anti-HIV antibody level during therapy.MethodsA prospective study was conducted to collect plasma samples of newly diagnosed HIV/AIDS patients from July 2018 to May 2019 in jiangmen city and follow-up.The purpose was to analyze the regional distribution,population characteristics and HIV-1 gene subtypes,and detect HIV-1 viral load with a new fluorescence quantitative PCR method.We also measured a comprehensive assessment of HIV-1-specific antibody levels in subjects who initiated ART during chronic HIV infection and AIDS phase using high-throughput luciferase immunosorbent assay(LISA).A line regression established to compare differences in decay rates,suppression degree and clearance time of anti-HIV antibodies among the two groups.Spearman correlations were calculated to investigate the associations between antibody titer and CD4+T cell counts with HIV RNA in plasma.ResultsAmong the study population,there were 158 newly diagnosed HIV/AIDS patients,64 were recorded before and 3,6,and 10 months after treatment,of which 40 were chronic HIV-1 infected and 24 were AIDS patients.The average age is 46 ±15 years old,mostly male(68.8%),predominantly married(56.3%),low employment rate(32.8%),high proportion of sexual transmission(87.5%),most of them through EFV+TDF+3TC treatment.The genotypes of HIV/AIDS patients were mainly CRF07_BC and CRF01_AE,accounting for 43.7%and 26.6%,respectively.Compared with HIV-1 infected persons,the incidence of p17 in WB bands of AIDS patients was lower(P=0.025<0.05),clinical symptoms were obvious.The new assay have a dynamic linear range from 4.0×102 to 4×10~7 copies/ml.The sensitivity,specificity,false negative rate and false positive rate were 91.67%,100%,8.33%and 0.00%,respectively.There was a strong correlation between this assay and a commercially available test kit(r=0.916,P<0.001).The levels of anti-HIV-1 antibodies in AIDS patients before treatment were lower than those in HIV-1 infection.After 10 months of antiviral therapy,the rate of antibody decline and the degree of inhibition differed between the two groups.The anti-integrase antibody of AIDS has the fastest decline(-0.14 log LU/month),and the anti-protease antibody has the slowest decline(-0.06 log LU/month).The clearance required is 25.50-33.83 months.The treatment time was wave-shaped;the rate of antibody decline in HIV-1 infected patients was between-0.26 and-0.12(log LU/month),and the clearance time takes 15.33-22.07 months.After antiviral therapy,the decrease of anti-pr antibody predicted the decrease of viral load,and the decrease of anti-in and gp41 antibodies affected the rise of CD4+T lymphocytes cell counts..ConclusionsCompare to chronically HIV-1 infected,a slower decline rate and lower suppression degree tested in AIDS patients who receiving ART for the first time.To some degree,the trend of anti-HIV antibodies can monitor the effect during ART in HIV/AIDS.